A combination of the two anti-tuberculosis, bedaquiline and dentin drugs, was found safe and effective in a small group of children and adolescent patients who suffer from infectious disease. At least 18 small patients have been placed on these drugs at an independent clinic Médecins Sans Frontières (MSF) in Govandi to produce a regular sputum version (samples tested for bacteria) and overall development.
Dr. MSF's activity manager. Pramila Singh found that none of the 18 patients who had been injured on the new drugs were suffering with any bad effects which had to be admitted to hospital or stopped treatment. “We have suffered patients with the most complex form of TB against drugs (XDR) or those in pre-XDR level on the latest drugs. To date, our comments and reports show that drugs have not made a significant impact. The toxicity of these drugs was much less than widely used drugs, ”said Dr Singh. The youngest of the four year olds is four years old and the older age 17. She says that the patients are there for a mixture of bedaquiline and demangen, or just demanage.
In accordance with the Program for TB in Bad Drugs in India guidance patients can be given to men aged between six and 17 years, but bedaquiline cannot be given to patients under 18 years of age. old. , extending bedaquiline to patients from six to 17 years of age and a decay for children over three years.
“We've been offering the latest drugs to younger patients as part of a focus group. These patients had no other drug use because of the complexity of the illness, ”said Professor Singh. She said that wider distribution of new drugs is essential.
From 2016, an MSF independent clinic has had 210 patients on the new drugs. Out of these, 155 are in the combination of bedaquiline and deciduous. Nearly 60 patients are free.
The Chest Consultant Dr Zarir Udwadia from Hinduja Hospital said so far, only 1,364 patients in India received bedaquiline. “In South Africa, more than 16,800 patients are on drugs and the country has already made a change in the number of drug drugs,” said Dr Udia. The WHO has recently pushed bedaquiline to the A group of drugs because of its efficacy of use and a drop in detachment to a group C. “Sorry that 2% of the drugs The crowd get bedaquiline. It is likely that our authorities are protecting the drug instead of protecting the patients, ”he said.